



2024 FISCAL YEAR • PUBLISHED JUNE 2025



AMNEAL 2024 Responsible Business Report

Table of Contents

Introduction	3	Our People & Practices	19
Message from Our Co-CEOs	4	Our People	
About Amneal	5	• Employee Health, Safety & Well-Being	20
Our Approach to Responsible Business	6	• Talent Recruitment, Retention & Development	21
2024 Responsible Business Highlights	7	• Our Global Workforce	23
		• Community Impact & Corporate Philanthropy	25
Our Societal Impact	8	Our Practices	
Access & Affordability	9	• Compliance & Business Ethics	26
Scientific Innovation	11	• Cybersecurity	28
Product Quality & Patient Safety	12	• Responsible Procurement	29
Our Environmental Impact	14	Appendix	30
Climate Mitigation & Resilience	15	Global Reporting Initiative (GRI) Index	31
Renewable Energy & Energy Efficiency	17	Sustainability Accounting Standards Board (SASB) Index	38
Waste & Water	18	Forward-Looking Statements	41

About This Report

The 2024 Responsible Business Report is Amneal Pharmaceuticals, Inc.’s (Amneal’s) fifth annual report. Amneal has continued to evolve its ESG commitments — and this report reflects our continued progress.

In this year’s report, we honor our 2024 commitment by disclosing Amneal’s greenhouse gas emissions data, along with select waste and water data. Collecting this data has been a considerable undertaking and a critical step toward establishing a foundation of reliable data that will drive our reduction efforts. Our 2024 report is mapped to the Sustainability Accounting Standards Board (SASB) index aligned with the Biotechnology and Pharmaceuticals Standard, and has been developed with reference to the Global Reporting Initiative (GRI) Standards as well as the United Nations Sustainable Development Goals (UN SDGs). We have selected the most pertinent SDGs against which this report is mapped to demonstrate Amneal’s influence and impact. Unless otherwise stated, this report details Amneal’s ESG performance and other non-financial disclosures covering the period of January 1, 2024 through December 31, 2024.





Introduction

IN THIS SECTION

- Message from Our Co-CEOs
- About Amneal
- Our Approach to Responsible Business
- 2024 Responsible Business Highlights

Message from Our Co-CEOs

We make healthy possible. That’s a powerful statement of our purpose and the value we seek to deliver for patients around the world.

For 23 years now, our teams have pushed the limits of what’s possible to responsibly make medicines accessible for those who need them. That effort has produced an expansive portfolio of more than 280 top-quality pharmaceutical products, new advances in operational efficiencies and an impressively skilled team.

But we’re not stopping there. Our ambition is to be regarded as one of the most trusted companies producing affordable and essential medicines. This report details some of the progress we’ve made in increasing access, reducing environmental impacts and elevating the communities we love, including our own Amneal family.

As a company founded on the principle that medicine should not be a privilege, we’re proud that Amneal delivers more cost savings and value today than at any point in our history. In 2024, our Affordable Medicines segment (including generics, biosimilars and injectables) filled more than 160 million scripts in the U.S., saving patients an estimated \$18.25 billion.

We also celebrated notable additions to our portfolio, including CREXONT® for Parkinson’s disease as well as a lower-cost over-the-counter Naloxone HCl nasal spray to help patients and communities combat opioid overdoses. Equally important, we worked to alleviate national drug shortages by producing more than 10 critical injectable medicines on the American Society of Health-System Pharmacists (ASHP) shortages list.

Our contributions to the world would not be possible without our people, who champion innovation, quality, digitization, operational efficiency, environmental stewardship, corporate philanthropy and so many other aspects that enable us to deliver impact. To ensure our employees are thriving, we prioritize their well-being and advancement. Key highlights included expanded benefits, the introduction of innovative career development programs and the receipt of multiple awards recognizing our commitment to women in India.

Alongside caring for our employees, we also acknowledge the role a clean environment plays in supporting good health. We had notable wins in the reduction of overall air and water pollutants and celebrated the release of our first comprehensive Scope 1 and 2 greenhouse gas emissions, energy and water use data sets in this year’s report. This baseline data will help us grow our environmental commitments in the coming years.

From energy efficiency and renewables (SDG 7: Affordable and Clean Energy) to delivering affordable access to high-quality, essential medicines in a sustainable and conscientious manner (SDG 3: Good Health and Well-Being), our responsible business efforts are accelerating positive social impact.

We thank our Amneal family of employees for making the world a better place. We also thank our patients, customers, suppliers and shareholders for your ongoing trust and support. You have our promise that we’ll continue to make healthy possible for all who depend on us.



Sincerely,
Chirag and Chintu

Chirag Patel

Chintu Patel

Amneal Co-founders & Co-CEOs

About Amneal

We Make Healthy Possible

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceuticals company dedicated to expanding access to safe, effective, and affordable medicines.

We develop, manufacture and distribute a diverse portfolio of 280+ high-quality medicines, primarily within the U.S. and India markets. Our business delivers value and impact via three reporting segments: Affordable Medicines (including retail generics, injectables and biosimilars), Specialty (innovative branded pharmaceuticals focused on central nervous system and endocrine

disorders) and AvKARE (distribution for the U.S. Federal government). A series of strategic investments over the years has bolstered our world-class scientific rigor, production capabilities and commercial infrastructure. We have also invested in our people through leadership development and employee well-being programs. Together, these advancements have accelerated our ability to deliver innovation and more complex products, while broadening portfolios in new categories and geographies. For us, medicine is personal. From affordable access to innovative therapies, we combine heart with precision to tackle tomorrow's health challenges head-on. We're building a world where none of our loved ones — regardless of circumstances — struggle to obtain the treatments they need.

Elevating access
to essential
and innovative
medicines



Our Approach to Responsible Business

Amneal was founded on the principle that medicines should not be a privilege; they should be accessible to all. For more than 23 years, our dedication to corporate responsibility has been integral to delivering on that promise. In recent years, we’ve expanded and formalized our efforts to include regular environmental, social and governance reviews to help establish baselines and inform the development of future goals. We published our inaugural Corporate Responsibility (ESG) report in 2020, with annual reports released every year since.

While Amneal has always pursued a social purpose, we began our formal ESG journey in 2021. Our first steps included learning, establishing structure and processes, and preparing for evolving regulatory requirements.

Initially, this included a discovery period about company activity, crafting our ESG narrative in a thoughtful and structured manner, and establishing infrastructure for tracking global GHG emissions at 34 facilities.

By 2023, we completed our first materiality assessment, expanded our ESG task force and bolstered our internal team. This year, as sustainability disclosure regulations increased worldwide, we undertook our first double materiality assessment. The results helped identify key areas of focus, including regular peer analyses for issues and progress, building dedicated global resources, enacting a governance model, quantifying our GHG footprint, enhancing structure for employee growth and well-being, and strengthening our responses to third-party assessments.

We’ve also identified several goals for 2025 to further advance Amneal’s sustainability positioning, such as developing a tailored framework and corresponding report to provide structure around priorities and more deeply integrating sustainability into our business strategy. We have implemented clear and robust policies, procedures and governance, and are succeeding in the optimization of many quantitative metrics. As we look ahead, we are committed to making progress on metrics not yet established, including the enhancement of GHG data. We are also aligning company programs to further differentiate Amneal from our competitors.

MOVING FORWARD, TOGETHER, TO MAKE HEALTHY POSSIBLE



Our Societal Impact:
Expanding Access While Driving Safety & Quality

Healthcare is always evolving. So we do what is necessary to develop safe, quality medicines. And then we make sure that they are accessible and affordable to all who need them.



Our Environmental Impact:
Working Smarter to Scale Our Global Impact


Expanding access means finding new ways to do things. That’s why we operate nimbly, using energy and resources wisely to maximize the number of patients we can reach.



Our People & Practices:
Creating Win-Win Solutions Through Responsible Business

To us, good business means doing the right thing by our patients, our communities and our colleagues. We are committed to transparency, employee well-being and philanthropic engagement.

2024 Responsible Business Highlights





OUR SOCIETAL IMPACT

Expanding Access While Championing Safety & Quality

Healthcare is always evolving. So we do what is necessary to develop safe, quality medicines. And then we make sure that they are accessible and affordable to all who need them.

IN THIS SECTION

- Access & Affordability
- Scientific Innovation
- Product Quality & Patient Safety

Access & Affordability

Amneal traces its origin story to a pharmacy in New Jersey where Co-CEO and Co-founder Chintu Patel witnessed firsthand the difficulty many of his patients faced in affording their medicines. Believing there had to be a better way, he teamed up with his brother Chirag’s business savvy and his father Kanu’s guidance to form Amneal in 2002. The company’s deeply generic heritage and mindset means we deliver medicines with a sharp lens on innovations that drive efficiency and affordability.

Amneal grew to be the #1 U.S.-based company in the U.S. generics industry by total scripts. Fueled by that success, we began diversifying the business to include increasingly complex products where historically expensive medications were a barrier for patients. Today, Amneal’s portfolio spans generics, injectables, biosimilars and specialty medicines. Despite the complexity of each of these areas, we remain true to our founding principles. The products we deliver to market stand for high quality, safety, efficacy and affordability.

We believe the healthcare system can be better — more accessible to more people — and we are part of the solution. In addition to the value we deliver through our portfolios, we also serve as strong public health advocates. We collaborate with government agencies, trade associations, coalitions and nonprofit organizations to support pre-pandemic planning, health focused initiatives and community-based programs — particularly those that reduce healthcare barriers and disparities in underserved populations.

We share SDG 3’s vision for safer, healthier and stronger communities. So we’re exceptionally proud of the multi-faceted role we play in delivering the innovation, resources and expertise that enable patients to access the medicines they need. We’re also paving the way for the continued success of our industry and increasingly advocating for government policies that prioritize access for years to come.

Sound Health Policies

Healthy healthcare is supported by sound policies across the many government agencies tasked with regulating the industry and delivering key programs and services. To ensure our voice is heard on matters that affect our industry and the people we serve, Amneal employees hold key roles in policy and public education.

As a champion for accessibility, we collaborate with the U.S. FDA as well as state and federal legislators to share our perspectives and advocate for policies that enhance access to safe, high-quality and affordable medication. We are also amplifying our voice in Washington, D.C. to advocate for policies that support a robust generic and biosimilars industry so we can continue to provide access and affordability for patients.

Alongside our policy activities, we’re also working with the U.S. government to address drug shortages and incentivize competition in the domestic manufacturing of essential medicines. These activities help establish a more resilient supply chain and elevated access to the healthcare patients need to live better lives.



Domestic Policy Advocacy

Maryll Toufanian, Senior Vice President, Regulatory Strategy and Government Affairs, assumed the role of Chair of Securing American Medication Supplies (SAMS) this year, leading efforts to secure the domestic supply chain for drug products. She also serves on the board for the Association of Accessible Medicines (AAM), an integral part of the U.S. healthcare system for Affordable Medicines and Biosimilar pharmaceuticals.

“Serving on multiple committees dedicated to improving healthcare access and affordability in the U.S. is a role and responsibility I take seriously. I’m grateful for the opportunity and look forward to continuing advocacy for patients at the federal level.”

Maryll W. Toufanian
Senior Vice President,
Regulatory Strategy and
Government Affairs



Access & Affordability

Accessible Medicines

We believe that everyone should have access to the medicines they need. It’s why we work relentlessly to expand our portfolios with an eye toward even greater patient options for access and affordability. In 2024, we can highlight several proof points of this commitment in action.

Our Affordable Medicines segment delivers a large and growing portfolio of high-quality retail generics, injectables and biosimilars at a great value, with \$18.25 billion in estimated savings delivered to U.S. patients in 2024 alone. Over the last several years, we have shifted our focus to more complex products with the vision of making historically expensive medications more easily accessible to patients.

We launched 22 new products last year in our retail generics portfolio, which already contains more than 240 value-focused products. We also deepened our work in biosimilars, which we see as the next wave of affordable medicines — providing lower-cost alternatives for important biologics. Our first three oncology biosimilars continued to experience commercial momentum and increased adoption by clinicians. Building on that, we added five additional biosimilars to our pipeline with launches targeted for 2026 and 2027.

In injectables, we launched three 505(b)(2) ready-to-use products that not only reduce cost but also improve provider efficiency and accuracy by eliminating medication preparation steps. With these innovative products, we finished 2024 with 12 new launches, bringing

the number of commercial injectables available for U.S. hospitals and health systems to over 40. Importantly, 12 of our injectables are helping to address persistent drug shortages of critical products on the American Society of Health System Pharmacists (ASHP) drug shortage list.

Our Specialty segment is heavily focused on serving the Parkinson’s and endocrinology communities. Ensuring access has always been part of our innovative process to develop and bring niche medicines to market. By partnering with providers along the patient journey, we do our part to help patients access the medicines they need to realize their best outcomes. This includes:

- A bridge program for patients who have initiated therapy, but who experience a delay in access to critical therapeutics.
- Free samples and a 30-day free trial prior to the patient’s benefits kicking in, so no one is forced to wait when it comes to starting life-improving pharmacotherapy.

In 2024, we were excited to launch CREXONT® (carbidopa and levodopa) extended-release capsules for Parkinson’s disease and have been encouraged by the strong response from prescribers and inspiring patient testimonials. Innovative treatments only realize their full value when patients can access them, so we worked hard to expand insurance coverage to approximately 30% by the end of 2024. We’ve continued those efforts into 2025 and are pleased with the >50% current coverage rate — demonstrating our commitment to broadening access.

Our company-wide focus on access and affordability

is further strengthened by Amneal’s patient assistance programs, which offer eligible individuals the opportunity to receive free medication for nine of our Specialty products for up to one year. In 2024, Amneal allocated more than \$5 million across multiple brands to support access for patients with the greatest need. We also offered various copay support and savings programs for an additional 15 products in our portfolio and dedicated nearly \$10 million in direct financial assistance through our copay assistance program. Together, these efforts helped more than 7,000 patients gain access to Amneal medications last year alone.

Outside of Amneal’s own programs, we have long partnered with external patient assistance foundations which help alleviate the financial burden of chronic disease. In 2024, we reinforced our commitment to supporting programs that make a direct, positive impact on patient care. In April 2025, we announced a \$1.5 million commitment with a direct focus on partnering with the Parkinson’s community.

We also support patients with out-of-pocket expenses through RedSail. The epinephrine auto-injector copay savings program helps independent, small-chain pharmacies access our products. The program has already helped drive meaningful cost savings. In total, Amneal has contributed \$34,500 toward helping patients with out-of-pocket copays for RedSail. At the end of 2024, we extended the program to cash-paying patients, in addition to those who are commercially insured.

Opioid Recovery Awareness

We recognize the detrimental impact the opioid epidemic is having on families across the U.S. We are passionate about and are providing resources to further educate and raise awareness about the crisis treatment options. For September’s Recovery Awareness month, we launched the “Taking Control Over It” initiative to raise awareness, reduce stigma and educate the community about OTC Naloxone HCl nasal spray and opioid emergencies.



We also partnered with advocacy organizations such as Remedy Alliance for the People, Mobilize Recovery, Young People In Recovery, NALCAM and The Naloxone Project. We donated more than 83,000 Naloxone nasal spray two-packs to various nonprofits and harm-reduction organizations. And we are proud to share updates about our partnership with iHeart Media’s Mobilize Recovery Across America Bus Tour.

Finally, in one of our largest, most impactful efforts, we partnered with the state of California to enable the purchase of lower cost Naloxone for its CalRx program. The CalRx partnership allows the state of California to greatly expand their distribution of free Naloxone nasal spray to qualified entities through via their Naloxone Distribution Program.

Scientific Innovation

Amneal’s Research & Development (R&D) is led by a world-class, in-house team supplemented by strategic product development partnerships. Our R&D ensures the ongoing innovation of important and value-generating products across our Affordable Medicines (retail generics, injectables, biosimilars and international portfolios) and Specialty segments.

Amneal’s R&D team is deeply experienced with a proven track record of building one of the industry’s largest generics pipelines and advancing our first internally developed Specialty product, CREXONT. In 2024, our Affordable Medicines pipeline contained ~56 pipeline programs and ~76 Abbreviated New Drug Applications (ANDAs) pending approval with the U.S. FDA. This pipeline depth reflects our shifting focus toward more complex products and enables us to sustain a new product launch rate of approximately 20-30 generics per year.

Our injectables pipeline includes 10 to 12 additional products in development as we focus on meaningfully expanding this portfolio to serve as a solution for the chronic shortages and supply chain issues plaguing U.S. healthcare. With our deep R&D capabilities and large injectables infrastructure, Amneal is well-positioned to be a leader in the space over the coming years.

We are also expanding our biosimilars portfolio. Building on the success of our first three commercial products, we have in-licensed five additional biosimilar pipeline candidates and expect to grow our portfolio to six biosimilars on the market across eight total presentations by 2027.

In our Specialty pipeline, our DHE autoinjector Brekiya® (dihydroergotamine mesylate) received FDA approval in May 2025 for the Acute Treatment of Migraine and Cluster Headaches in adults. When launched in the second half of 2025, Brekiya will be the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form. We will continue to optimize our R&D portfolio, allocating more resources toward biosimilars and Specialty over time.

Delivering Innovative Treatment for Parkinson’s Disease

In 2024, the FDA approved CREXONT (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease that combines both immediate-release granules and extended-release pellets.



The approval of CREXONT is a seminal moment in the treatment paradigm for Parkinson’s disease. Amneal is so excited to introduce this meaningful new treatment for Parkinson’s patients in the U.S. and soon internationally. We are committed to continuing to advance Parkinson’s research and development as a leader in the space.



Joe Renda,
Senior Vice President,
Chief Commercial Officer –
Specialty



We are excited to expand our biosimilar pipeline with the addition of five pipeline candidates across various therapeutic areas. We are building on the strong success of our first three commercial biosimilars and are helping to increase access and choice to patients and providers while also driving cost savings for the U.S. healthcare system.



Sean McGowan,
Senior Vice President,
Biosimilars and Branded
Oncology



Product Quality & Patient Safety

Quality has always been the core foundation of Amneal’s culture and business. Our family of employees is very aware that we make medicines not only for our own family members, but also for many others. Responsibility for product quality and patient safety is something we never take lightly.

Amneal’s quality track record is best-in-class because we operate our facilities with a relentless commitment to quality and compliance in all aspects of our operations and particularly in R&D, manufacturing and logistics. We also thoroughly vet all potential and current partners to ensure they continuously uphold our highest values and expectations.

For us, quality means getting it right the first time, every time. We are unwavering in our quality commitment, ensuring that neither patient safety nor customer satisfaction is compromised.

This commitment extends across everything we do, including our clinical trial standards for Specialty drugs, where we most recently designed Phase 4 clinical trials for CREXONT with zero feedback from the FDA during the 30-day review. We also adhere to all International Council for Harmonisation and Good Clinical Practice guidelines.

Amneal’s quality and safety efforts are thriving. Our 15 global quality control testing laboratories are audited by the FDA and EU regulatory agencies and are equipped with sophisticated instruments that deliver innovative in-house product testing capability. We follow current

Good Manufacturing Practices (cGMP) across all sites, following pre-approved Standard Operating Procedures (SOPs), Standard Testing Procedures (STPs) and protocols with batch records. And all employees are trained on cGMP, key quality system SOPs and respective work-related SOPs.

In 2024, we completed five successful U.S. FDA inspections and all concluded as No Action Indicated or Voluntary Action Indicated. Additionally, seven

regulatory and 12 customer inspections concluded with zero critical or major observations. Since our founding, the FDA has completed over 105 successful inspections of our facilities — with either no or only minor observations. We are incredibly proud of our team members who are leading the industry in product quality and safety.



inspections concluded as No Action Indicated or Voluntary Action Indicated



regulatory and customer inspections concluded with zero critical or major observations

Product Quality & Patient Safety

Quality is so critical to our business that we’re continuously strengthening our capabilities, processes and systems. Last year, we advanced our Quality Systems through digitization and automation. Digitization eliminates paper and enhances compliance and data integrity. Our latest efforts include the deployment of advanced software solutions, all of which are currently live or in progress with a target to implement by 2025:

- Laboratory Information Management System
- Quality Management System
- Document Management System
- Learning Management System
- e-Log Book (Quality)
- Market Complaint Management
- Incident/OOS Management
- Retain Sample Management
- CARES Act Drug Product Reporting
- Annual Product Quality Review Software

Looking Forward: Wisdom Vault

In addition to digitizing and harmonizing Amneal’s Quality Systems, we are also investing in knowledge and skill development globally. Wisdom Vault is one of the latest initiatives that will share critical information, such as industry advancements and learnings from other companies’ improvements. Wisdom Vault will also empower employees to learn by providing access to expert speakers, a webinar series for junior employees, a library of documents on regulatory topics and more. This program is expected to launch in 2025.

Building the “Factory of the Future” in India & Ireland

Amneal is making strong progress on Digital Analytics and Automation (DAA) with the implementation of Laboratory Information Management System (LIMS) across our facilities. DAA technology significantly reduces process cycle times and operational costs by simplifying workflows, automating tasks, eliminating unnecessary steps and making it easier to stay compliant with regulations.

Proof of DAA value is in our recent audits. At our India site, one investigator praised our “fantastic and robust system.” Our Ireland team has seen similar results with auditors acknowledging our competent employees and strong compliance and investment in technology and digitization. In fact, one regulator even shared a wish for other companies to adopt our high-standards approach to best manufacture sterile drug products.





OUR ENVIRONMENTAL IMPACT

Working Smarter to Scale Our Global Impact

Expanding access means finding new ways to do things. That’s why we operate nimbly, using energy and resources wisely to maximize the number of patients we can reach.

IN THIS SECTION

- Climate Mitigation & Resilience
- Renewable Energy & Energy Efficiency
- Waste & Water

Climate Mitigation & Resilience

Amneal has long been committed to meeting all required environmental regulations at the local, state and federal levels. By improving our positive impact, increasing efficiency and driving down costs, we strengthen our commitment to expanding access to essential medicines for communities around the world.

With this mission in mind, our ESG and Operations teams (including EHS and Engineering) began collaborating at a global scale in 2024. Members from all facilities across Ireland, India and the U.S. now connect regularly to discuss environmental and safety issues, initiatives and local progress, sharing insights and spurring innovation.

In 2024, we amplified our operational efficiency efforts by expanding our Kaizen continuous improvement program to identify and implement small-scale improvements in work areas. We introduced new facilities to the methodology and hosted Kaizen Fest in Brookhaven, New York. At the event, employees showcased their ideas for greater efficiency and leaders advanced appropriate suggestions for implementation. In early 2025, we continued to deepen the program, bringing Kaizen Fest to our New Jersey operations.

We also continued to strengthen our tracking of comprehensive data for energy, waste and water usage at all facilities per our GHG Investment Management Plan and as detailed to the right. In 2023, we laid the groundwork for enhanced environmental data management by introducing a new GHG accounting software, developing comprehensive documentation (an inventory management plan, SOPs and workflow documents), and establishing a robust data governance framework. In 2024, we focused on implementing these processes across our facilities in India, the U.S. and Ireland.

Key achievements in 2024 include:

- Appointment and training of dedicated data owners at each facility, establishing local expertise in GHG accounting and the utilization of the GHG accounting platform.
- Implementation of shared, auditable data tracking resources, ensuring data verifiability through supporting documentation.
- Improvement of GHG accounting process documents.

To further strengthen our data management, we are actively pursuing automation initiatives. This automation will enhance data quality and reduce reliance on manual processes, ultimately ensuring a highly controlled data environment that meets future regulatory requirements. Our approach remains firmly aligned with the Greenhouse Gas Protocol, reinforcing our commitment to standardized, rigorous and scalable GHG emissions data management across our global operations.

Defining & Disclosing GHG Emissions Data

Throughout 2024, we also sought to expand upon our 2022 and 2023 greenhouse gas emission data collection. We currently define our emission categories as the following:

SCOPE 1

Includes all direct emissions from sources owned by Amneal, and is further bifurcated into these categories:

- **Stationary Combustion** – Includes the use of fuels to produce electricity, heat or steam by any stationary equipment. Stationary equipment includes boilers, furnaces, turbines, heaters, incinerators, burners, dryers, ovens and any other equipment.
- **Mobile Combustion** – Includes fuel consumption from all Amneal-owned or leased transportation fleets such as cars, trucks, buses, forklifts, etc.
- **Fugitive Emissions** – Activity that directly releases GHG gases into the atmosphere from equipment and processes such as refrigeration and air conditioning systems.

SCOPE 2

Includes all indirect emissions from purchased energy, such as the electricity used in our facilities. Amneal does not purchase energy in the form of heat, steam or cooling at any of our facilities.

		2022	2023	2024
Number of Properties		33	33	34
GHG Emissions (mtCO ₂ e)	Scope 1	41,900	40,600	40,500
	Scope 2 (location-based)	101,700	102,100	102,400
	Scope 1 + 2 (location-based)	143,600	142,700	142,900
Energy consumption (million kWh)	All fuels	165.7	159.7	157.8
	Electricity	174.4	173.6	174.1
	Total	340.1	333.3	331.9

Climate Mitigation & Resilience

Air Quality

In Brookhaven, NY, we have a state-of-the-art Regenerative Thermal Oxidizer active on site with over 30 pieces of equipment to comply with New York State Air emission policies. We're also working to improve air quality at our New Jersey sites by upgrading older parts of our catalytic oxidizer to further reduce VOC emissions and keep our sites in compliance.



Green Team

This year, we launched a Green Team at the Brookhaven site, attracting 32 volunteers who meet periodically to discuss environmental strategies. One early success is the creation of four garden beds planted and cared for by employees. All vegetable and herb produce is picked by employees and taken home or placed in cafeterias for other employees to enjoy. Employees also plant flowers around the facility to attract and support the health of pollinators.



10,000+ Trees Planted Around the World

Building on the partnership established in 2023, we furthered our efforts with One Tree Planted, which works closely with local communities to create positive social and economic impacts by expanding forest cover. In honor of World Environment Day in 2024, we helped plant over 10,000 native trees in the U.S. and India. Once mature, these trees will create a carbon sink, helping absorb CO₂ while protecting soil.

Learn more about the impact we're co-creating with [One Tree Planted](#).



Transition from Coal to Biomass in India

Transitioning from the use of fossil fuels is one of the most important strategies our company is pursuing to quickly reduce our carbon footprint. This year, our India sites worked hard to make big changes. One plant in Visakhapatnam eliminated the use of roughly 140 tons of sub-bituminous coal every month in favor of a cleaner biomass fuel. Assuming similar production and use levels, we expect this transition to directly reduce roughly 1,600 tCO₂ emissions per year.

Renewable Energy & Energy Efficiency

Electricity is one of Amneal’s primary sources of emissions due to the amount of equipment needed to operate our facilities. We are taking proactive strides to reduce overall energy consumption across all our facilities, even as production increases, to honor our environmental responsibilities and drive costs down.

In New York, Brookhaven, one of our largest facilities globally, leads the way on energy efficiency. We have a Geothermal Well System that pumps water from the ground to use for heating and electricity, returning it back to the ground after usage — achieving efficiency and environmental responsibility. We have also created a plan to lower electricity emissions, with a long-term goal to install more LED lighting and renewable energy to support more efficient energy usage while lowering the amount of kWh our facility consumes.

In Ireland, we are also seeing positive momentum toward energy efficiency, with efforts to reduce our carbon footprint via diligent monitoring, reduction of human error, and energy consulting. Additionally, we source from renewable energy providers and are exploring alternative renewable sources such as wind, solar and biogas integration. We prioritize favorable energy procurement strategies that focus on suppliers with high renewable energy commitments.

Other short-term facility goals include creating efficiencies in overall systems, such as pumps, equipment and boilers. Optimizing boiler chemicals and steam traps helps create more efficient heating of our facilities and lowers natural gas consumption. Chilled water pumps, hot water pumps,

chillers, AHUs and precool pumps at facilities such as Brookhaven are all calibrated and balanced to lower the amount of energy required to run. This has led to 5,000,000 kWh saved per year.

These systems help us achieve our business goals by reducing our impact on the environment, driving down costs and ultimately increasing the affordability of our products.



Turning Down the Temperature

The Engineering and Safety team at our Brookhaven, New York facility installed a low-power mode in the Regenerative Thermal Oxidizer (RTO), a required piece of equipment that helps improve air quality by scrubbing Hazardous Air Pollutants (HAP) and Volatile Organic Compounds (VOC) emissions during periods of production. The RTO typically runs at 1600 F 24/7, 365 days per year. Installing a low-power mode decreases the RTO temperature to 400 F when not in production, leading to lower energy usage for the entire facility.

1600 F → 400 F



Driving Down Emissions

In 2024, our Brookhaven facility leveraged National Grid’s 2024 “Steam Energy Savings” program, which offered a \$100 rebate per replaced steam trap. Amneal completed a comprehensive survey that identified 265 faulty traps requiring replacement. We have now upgraded 120 traps, and the remainder are scheduled for completion soon.

The initiative delivers substantial environmental and operational benefits. Failed steam traps can continuously leak steam, wasting fuel. Replacing them reduces fuel use, so fewer GHGs are emitted, while reducing the facility’s overall carbon footprint. The improvements also help conserve water and reduce the demand for water treatment chemicals. Beyond environmental impacts, the replacements also optimize system performance by maintaining proper pressure and temperature while preventing costly water hammer and corrosion issues. This preventative approach extends equipment lifespan and reduces maintenance expenses.



Transitioning to More Efficient & Healthier Fuels in India

As part of our growing awareness of the importance of reducing our carbon footprint, leaders at the Rajoda and Matoda manufacturing plants in Gujarat, India, have made significant strides in upgrading to more efficient, lower-emitting fuels. Both plants have transitioned to Low Sulphur Heavy Stock (LSHS) fuel, supporting an 84% reduction of sulphur content, about 10% less carbon content and an overall reduction in the need for energy intensive centrifugation. The lifespan of our equipment has also been increased due to reduced corrosion from a lower sulphur content fuel, further driving cost savings and reducing environmental impact.



Our Environmental Impact


Waste & Water

We are also committed to better understanding our impact on waste and water. Across multiple sites we’re already seeing water pollutant reductions, including at our New Jersey facilities, where additional efforts in chemical selection, pH balancing and rigorous cleaning have reduced detectable levels of acetyl compounds in wastewater.

Additional diligence to establish baseline waste and water usage levels across our sites bolsters our reduction goals and will enhance tracking in the future.

Water Consumption

TOTAL CONSUMPTION
(MILLION LITERS)



Rainwater Harvesting Efforts in India

Rainwater harvesting ponds are an established method of water conservation, and thanks to our EHS Team at our Rajoda facility in India, the local plant conserved approximately 6,000 kiloliters of rainwater during the four-month rainy season (July to October, 2024).

Notably, the rainwater was mixed with treated water and reused in plant utilities. This not only reduced freshwater consumption, but also minimized the TDS/High TDS of final effluent disposed to common effluent treatment plants.

Going Paperless

Amneal quality teams have cut back on paper waste by adopting digital notebooks that can be wiped clean and reused, while notes can be digitally stored or uploaded to computer files. Initially launched for leaders at the Brookhaven, NY site, employees who consistently use notebooks are also taking up the practice to reduce paper waste.





OUR PEOPLE & PRACTICES

Creating Win-Win Solutions Through Responsible Business

To us, good business means doing the right thing by our patients, our communities and our colleagues. We are committed to transparency, employee well-being and philanthropic engagement.

IN THIS SECTION

Our People

- Employee Health, Safety & Well-Being
- Talent Recruitment, Retention & Development
- Our Global Workforce
- Community Impact & Corporate Philanthropy

Our Practices

- Compliance & Business Ethics
- Cybersecurity
- Responsible Procurement

Employee Health, Safety & Well-Being

We recognize that in order to make healthy possible for others, we must first make healthy possible for our colleagues. That’s why supporting employee health and well-being is paramount. We take pride in leading the industry in providing a comprehensive framework of programs and services that support our team members in achieving their individual physical, emotional and mental well-being goals. We also strive to offer an engaging, welcoming and supportive environment with improved quality of life for our employees and their families. This includes assistance with daycare services at select facilities in India.

Health & Well-Being

We prioritize employee needs, and providing great benefits is fundamental to retaining great talent. This year, we are excited to feature several key updates to our country-specific benefits packages.

We foster holistic well-being for our employees and their families through our AmWell program. In the U.S., this initiative has been powered by a leading digital well-being provider offering an extensive range of mental, physical and financial resources, content and services. To deepen value and encourage active participation, we enhanced AmWell with programs focused on mindfulness, meditation, nutrition, fitness, mobility and financial acumen. We also host wellness challenges throughout the year that spotlight different pillars of well-being and offer meaningful incentives to encourage personal achievements. By listening to employee feedback and regularly updating our offerings, we specifically tailor our benefits to support the financial, physical and mental well-being of our team. We are proud that 89% of our U.S. employees participate in our 401(k) plan (with company matches up to 5%).

In 2024, we also expanded the AmWell platform to our

Ireland colleagues while our India-based teams benefited from AmWell wellness solutions tailored to local needs. Our India-based AmWell programming has strong participation. In 2024, 4,575 eligible employees completed 9,183 health and well-being sessions, including 99% of employees completing their annual health check-ups. Over 3,000 employees also actively participated in onsite and online fitness sessions, such as Zumba and yoga, while 1,283 employees participated in financial well-being initiatives, enhancing their ability to make informed decisions. In addition, 1,608 employees participated in mental well-being sessions.

In India, we also enhanced physical health offerings and are proud to report a 12% reduction in disease rates among participants. This important achievement has greatly improved local employee health and was driven by the introduction of new employee exercise programs that target cardiovascular health, preventing a leading cause of disease and death.

Supporting employee health before illness is a core part of Amneal’s health and wellness goals. We are building on last year’s momentum in 2025, with the continued expansion of our benefits, including family, health and financial wellness programs.

Success in Workplace Safety

Workplace health and safety is essential to delivering safe, effective products. We bolstered our workplace safety efforts with monthly safety education campaigns and continued deployment of our IndustrySafe application, supporting enhanced incident reporting and analysis of safety metrics across all geographies. Colleagues also demonstrated our continuous safety focus by participating in World Health and Safety Day across our global sites.


These efforts supported the achievement of our goal of <2.5 Total Recordable Incident Rate across all sites globally. Recordable incidents have dropped every year for five years, despite a continuously growing global workforce. In 2024, we achieved our lowest recordable incident rate yet as a result of increased training and floor inspections.

Safety programs and SOPs are designed to monitor and control hazards such as flammable and combustible



materials, forklifts, control of hazardous energy, exposure to hazardous materials/products and respiratory programs. Inspections are conducted to ensure employees are coached on proper safety protocol procedures. We have also implemented IndustrySafe tracking software to assist in automating the monitoring of incidents, reporting and corrective actions at all sites in the U.S.


Amneal maintains strong employee safety participation and awareness through focused safety initiatives, including required training, industrial hygiene monitoring, incident oversight and optimized workplace safety investments. Employee engagement also remains high in key health and safety awareness campaigns and through active involvement in the Employee Safety Steering Committee.



Talent Recruitment, Retention & Development

We pride ourselves on attracting and retaining top talent to foster the innovation necessary to continue the positive impacts our business contributes to the world. In 2024, we expanded our #WeAreAmneal recruitment efforts, launched a company-wide talent management program called MyAmneal Career, and evolved our signature leadership development initiative Amneal Leadership Lab. By doing so, we are doubling down on our investment in our most valuable asset — our Amneal team.

Talent Recruitment



In 2024, we developed a new employee value proposition to facilitate quality hires in a competitive talent marketplace. The effort was a global, bottoms-up initiative that drew inputs from employee focus groups, HR and the executive leadership team to help better communicate Amneal’s value to prospective employees. The resulting “#WeAreAmneal” campaign has been integrated into various recruiting and external communications.

We are pleased to offer a broad, flexible and competitive benefits program that enables employees to choose the plans and coverage that meet their personal needs.

These robust programs, which vary by country, include basic and supplemental health and insurance benefits, health savings and flexible spending accounts, access to a personal health advocate, paid parental leave for birth, adoption or foster placement, family leave, employee assistance programs, travel assistance, tuition reimbursement assistance and retirement savings plans. In addition, we offer a remote work policy that enables eligible U.S.-based employees the flexibility of a hybrid work schedule of three days onsite and two days remote per week.

Our Rise Internship program was formalized in 2024 to help engage students interested in our industry. We sponsored 55 U.S. students from accredited universities and curated immersive and critical industry experiences to support their careers.

Talent Retention

We attract and retain talent and reward performance through our robust Total Rewards program, which includes industry competitive benefits, compensation and recognition offerings. Our compensation program includes competitive base salaries, annual cash performance-based incentives, equity-based long-term incentive awards and cash-based long-term incentive awards for eligible employees. In 2024, 10%+ of our global employees earned promotions as part of our annual review process.

Recognition is a core element of our culture. In early 2024, we reimagined our global employee recognition program

with the launch of a new Amneal Achievers digital platform supported by learning sessions on how gratitude can create connections, convey impact and foster belonging. By the end of 2024, impressive engagement resulted in nearly 55,000 unique recognitions shared between colleagues. These recognitions were further amplified over 50,000 times by other peers boosting, liking and commenting within the platform.



Employee Benefits

Employee benefits are part of what differentiates our company. In 2024, we demonstrated our leadership in this area by avoiding employee health cost increases despite most of the U.S. market experiencing a 5% increase in medical costs. We also added several new employee benefits. By holding the line on raising employee benefits costs, we can improve overall financial and mental well-being while also making Amneal an attractive place to achieve personal goals.

Employee Retention in India

Workforce retention remains well above national averages in India, with 70% of our employees having a tenure of ten years or greater with Amneal. We attribute this to a combination of our skill-based career progression opportunities as well as our rank in the top quartile of the industry for our employee benefits and recognition efforts. Retention programs designed specifically for women are also underway to ensure we are supporting underrepresented populations in India.



Talent Recruitment, Retention & Development

Employee Engagement

Employee listening and engagement are important aspects of our culture and colleagues are encouraged to share their opinions, insights and ideas. We collect and measure feedback through various channels, including town halls, leadership retreats, company email boxes and our Amneal Listens program.

In 2024, we leveraged Amneal Listens to measure employee engagement. We increased the reach of our annual survey to include our entire global workforce. Global employee engagement rose to 88%, 11 points higher than the pharmaceutical industry benchmark, and reflects employees

feeling valued, excited by their work and motivated to contribute more than expected. We also noted very high scores on confidence in Amneal (91% favorable on efforts to advance strategy) and retention (81% plan to stay with Amneal for the next three or more years). Our India site recorded a remarkable 97% employee participation rate — a testament to Amneal’s strong culture of engagement within our global teams.

Even with these results, we are taking additional actions to strengthen engagement. These efforts include expanding opportunities to grow via a robust career development program (design of subsequent phases of MyAmneal Career, including a talent marketplace and skills library, were initiated in 2024) and supporting functional leadership in addressing key survey themes across the business.

Talent Development

To strengthen company-wide talent management capabilities and individual growth opportunities, Amneal was proud to embark on the development of a new global job architecture initiative in 2024 called MyAmneal Career. This program, which primarily focuses on talent management, retention and career development, will offer employees a new skills-based ontology with detailed information about how their role fits within the overall organization’s talent architecture. It will also provide employees the opportunity to visualize potential growth tracks and then empower them to seek and improve new skills to climb the ladder. In 2024, we completed the development of the job architecture, and look forward to building the skills ontology and career tracks in 2025.

The initial phase of MyAmneal Career organized global jobs, defined career tracks and job families, and provided enhanced clarity to colleagues about their roles. In the coming year, we are stimulating a development mindset for leaders and employees via workshops and learning resources on topics including career aspirations and skill development. A new AI-powered Talent Marketplace will be launched in 2025. The program will enable employees to create their talent profile, learn about roles/required skills in the organization, and explore career paths, skills-based trainings, gigs, mentorships and more.

Enhancements to MyAmneal Career will continue throughout 2025 and beyond, and we look forward to sharing our progress and impact. Our hope is that this robust program will help provide an even stronger foundation for ensuring pay and title equity while providing all employees with a sense of satisfaction and ambition to grow with us.

Supporting Rising Leaders

Amneal Leadership Lab is the signature program delivered by our global Learning & Development team. The program is customized for Amneal and operates under the premise that all employees can lead regardless of role, location or function.

In 2024, we strengthened management and leadership skills through continued investment in professional development. We expanded the Amneal Leadership Lab curriculum by leveraging recognized external experts who collaborated with senior leaders on Leadership Practices, including Recognition, Inclusion & Belonging, Managing Energy to Sustain Momentum, and Listening for Collaborative Dialogue. The core program cascaded across the organization and

covered psychological safety and direct conversations, building trust, effective decision-making, and leading and embracing change. Additionally, we expanded offerings of our Management Standards curriculum — a series of eight workshops designed for new people leaders covering best practices for elevating manager effectiveness and creating positive employee experiences.

In 2024, our Leadership Lab supported 3,652 global learning hours across the following programs.

- **Amneal Leadership Lab Core:** 67 different participants engaged in at least one of a five-session leadership development program, for a total of 208 learning hours.
- **Amneal Leadership Lab, Driving the Business:** 221 different participants engaged in at least one of five courses focusing on senior leader development, for a total of 389 learning hours.
- **Amneal Leadership Lab, Management Standards:** 286 different participants engaged in at least one of eight courses targeting manager effectiveness for new people leaders, totaling over 1,400 combined learning hours.
- **LinkedIn Learning:** Colleagues engaged in 1,570 learning hours — more than double the total in 2023 — via over 1,600 active licenses.

In addition to our Amneal Leadership Lab initiative, in India, our Young Women Leadership Development Program successfully prepared 23 female employees for their next role with our company. Our Frontline Development Program trained more than 100 frontline employees on essential leadership skills. We also launched our Leader Speak and Amneal Accelerate bite-size learning initiatives, which reinforced our culture of continuous learning.



Our Global Workforce

As a leader in healthcare, we believe in the value of bringing new ideas, skillsets and perspectives to help power innovation and progress. Fostering an environment where all employees can bring their best selves to work and truly experience inclusion and belonging enables us to learn, grow and deliver even more value together.

As of December 31, 2024, six out of our ten executives identified as diverse by race, ethnicity or gender. More broadly, approximately 74% of our U.S. workforce identified as diverse by race or ethnicity. Women represented 21% of our global workforce.






1,935
New Employees



871
Promotions

WORKFORCE REPRESENTATION



Our Global Workforce

Award-Winning Successes in India

According to the World Bank, fewer than 13% of women are in senior- or middle-management roles in India. As a result, the country’s Ministry of Labor and Employment has made it a national priority to engage and support women in the workplace.

To align with local initiatives, we set an ambitious goal to significantly increase female representation within our business operations in India. We began with a base of 7.84% female employment in February 2023. As of December 2023, that number rose to 9.28%, and, by the end of 2024, female representation grew to 11.4%. We expect this trend to continue through 2025 and beyond.

We are especially dedicated to identifying more roles for women and are collaborating with department heads to ensure these positions are filled with qualified female candidates. This approach is central to our goal of increasing female involvement across all levels of the organization in India. We currently have seven ERG Core Committee members and 57 Site Champions who assist in facilitating quarterly ERG meetings to generate ideas, track progress and create a supportive environment for the women we hire. In under two years, women now represent 5.66% of leadership roles on site, with 12 female leaders among 212 senior employees.

AmNeeV is Amneal’s flagship initiative in India aimed at preparing women with the skills necessary to enter work in the pharmaceutical sector. The program made remarkable strides in 2024. We became the first pharmaceutical company to conduct a walk-in recruitment drive exclusively for women, drawing interest from 1,400 participants. From

this pool, 84 women were selected into the AmNeeV training program. The training blended theoretical learning with hands-on practical experiences in areas such as UV, HPLC, FTIR and pH calibration.

Over three months, participants learned to master critical techniques, took courses designed by Amneal’s subject matter experts, studied intensive SOPs, and practiced report writing exercises. Through AmNeeV, 94% of participants cleared the interview and were deemed industry- and Amneal-ready. Final participants were presented with a Gold Medal from the Honorable Governor of Gujarat for their exceptional achievements.

I’m incredibly proud to share that I have received a gold medal from the Honorable Governor of Gujarat Shri Acharya Devvrat at the Convocation Ceremony. Thanks to Amneal for shaping our future and providing opportunities to make us industry fit and providing job opportunities.

Gold Medalist Student
Krutika Sonar,
the highest scoring AmNeeV participant in
Quality Control and Trainee Officer in the
Quality Control Department

The Young Leadership Development Program (YLDP) has also catalyzed meaningful gains in female representation in India. By providing a structured roadmap to success, YLDP offers women targeted training, real-world projects and personalized development plans over an eight-month experiential leadership journey. Participants are selected through a structured process that identifies high-potential female candidates through aptitude tests.

We also recognize the importance of cultural sensitivity to foster a welcoming workplace. This year, 500 employees were included in inclusion and belonging as well as unconscious bias awareness training. Sixty leaders participated in gender sensitivity workshops, and 30 more were trained and certified as Prevention of Sexual Harassment Internal Committee (POSH IC) members. We are humbled that these initiatives have earned our Human Resources team in India the honor of Best Practice Award for Promoting Inclusion at the Workplace 2024 by the Confederation of Indian Industry (CII).

Finally, the Buniyaad Initiative extends Amneal’s commitment to India by welcoming families to experience firsthand the supportive environment Amneal provides for their loved ones. This includes facility tours, storytelling and fostering a family-friendly environment that inspires trust, loyalty and shared purpose. Our hope is that the training supports the familial stability necessary to attract and retain talent, including women.

“

Our strategic focus in India aligns with local initiatives to strategically increase the number of women in leadership and empower them through targeted programs like AmNeeV. With this program and initiatives like the YLDP, we are developing a robust pipeline of talented female professionals. We are proud of the progress we’ve made and remain steadfast in our dedication to increasing gender diversity in India.

”

Rahul Maitra
Senior Vice President,
Human Resources

Community Impact & Corporate Philanthropy

Alongside our unwavering commitment to delivering accessible medicines, we also believe in supporting the communities in which we live, work and serve. To this end, our team sought to increase our philanthropic efforts over the prior fiscal year. Our U.S. sites alone ultimately donated more than 235,500 product units and over \$500,000 in financial contributions. This included an intentional process to identify organizations and projects that best reflect our commitment to patients, community and the environment.

One of our biggest projects this year was the donation of 83,000 Naloxone units to various nonprofit and harm-

reduction organizations. Our additional philanthropic efforts included ongoing support for recipients such as AmeriCares, Dispensary of Hope, Direct Relief, One Tree Planted and Heart to Heart International, with whom we support the development and dispersion of personal hygiene kits. We also offered a hurricane relief fund for the disasters that struck the Carolinas and Florida. A full list of the organizations we support can be found on Amneal’s website.

Furthermore, we continue to see significant growth in staff participation for the Michael J. Fox Parkinson’s Unity Walk, with over 150 Amneal employees supporting

the annual New York City-based charity event this year. At more than double our 2023 participation levels, we are so proud that our Amneal family truly shows up to support a community near and dear to our hearts.

Finally, in recognition of our employees’ needs, Amneal began laying the groundwork for developing an employee relief fund. The fund is intended to ensure team members have access to the support they need in difficult times. We are excited to launch and expand this program in the upcoming year.



**Dispensary of Hope,
by the Numbers**



166,000
patients served by Dispensary
of Hope in 2024



273 number of dispensing
site locations



121 million
total doses distributed through
our program in 2024



1.2 million
total prescriptions filled
through our program in 2024



29.8 million
Amneal doses donated
throughout partnership
(since 2012)

Compliance & Business Ethics

ESG Risk Management

Amneal’s management team is responsible for managing the day-to-day risks we face. Our Board of Directors (Board) is responsible for:

- Confirming that management has implemented an appropriate system to manage these risks, i.e., to identify, assess, mitigate, monitor and communicate about these risks; and
- Providing effective risk oversight through the Board’s committee structure and oversight processes.

Beyond these fundamental responsibilities, our Board concentrates on the broader implications of our strategic plans and allows the committees to focus on specific areas of risk. Our directors, through their risk oversight role, are responsible for confirming that the risk management processes designed and implemented by our executive officers and other senior managers are consistent with our corporate strategy and are functioning as intended. The Board believes that full and open communication between management and the Board is essential for effective risk management and oversight. In addition to making presentations at our quarterly meetings of the Board or committees thereof, our executive officers are available to discuss any questions or concerns raised by the Board relating to risk management and any other matters. In addition, information technology leadership typically reports on cybersecurity matters to our Audit Committee at least twice a year.

Nominating and Corporate Governance Committee

The Nominating and Corporate Governance Committee assists the Board in fulfilling its oversight responsibilities with respect to the management of risks associated with corporate governance. This includes Board structure, size, membership and succession planning for our directors, as well as ESG matters of importance to the company. The Committee also assists in carrying out our commitment to ESG principles and diverse representation on our Board.



Compliance & Business Ethics

Compliance

We strive to conduct all aspects of our business in accordance with the highest standards of business ethics and to comply with all applicable laws and regulations that govern our industry, globally.

As part of this effort, we have established an effective enterprise-wide Corporate Compliance Program designed to identify and address risks through critical thinking and collaboration with business partners. The Corporate Compliance function promotes transparency by identifying opportunities to reinforce that compliance is everyone’s responsibility. Our Corporate Compliance function routinely conducts auditing and monitoring of business activities — in cooperation with our Internal Audit team — to assess adherence to company policy, identify potential training needs and ascertain the need for policy development or modification.

Oversight of the Compliance Program

Our Vice President, Corporate Compliance, has primary responsibility for development and implementation of our Corporate Compliance Program. This includes drafting policies and procedures, training, monitoring, performing investigations and responding to identified problems. The Vice President, Corporate Compliance, provides quarterly reports on the operation of the Compliance Program to the Audit

Committee of the Board, the body with oversight of our Compliance Program.

Code of Business Conduct

After a refresh of our Code of Business Conduct in fiscal year 2023, we observed the successful implementation of those changes in 2024. This was critical to ensuring our values and standards are as up-to-date as possible. All employees complete and attest to understanding the Code of Business Conduct training, and are required to familiarize themselves and follow the principles set forth. Amneal is committed to reviewing and updating this code as needed.

Speak Up Culture

We encourage a culture where employees can speak up without fear of retaliation. Our hotline is referred to as the Amtegrity Line. The Amtegrity Line empowers employees to speak up on issues of potential concern and provides us with information to remediate alleged issues and improve internal processes.

Compliance Education & Training

Education is a key element of our Corporate Compliance Program. As such, we integrated Compliance Training within our new learning management system (LMS) in 2024. This new LMS is designed to provide our

employees with information needed to execute their job responsibilities in an effective and compliant manner and to help employees better understand the impact of their actions on Amneal and society as a whole. Upon joining Amneal, employees receive comprehensive training on requirements that pertain to our industry, general compliance matters and their specific job functions. Employees continue to receive compliance training when relevant changes are made to the policies or regulations that govern their business conduct. We review and update our training programs periodically to increase clarity and effectiveness and to identify areas where additional training is needed.

Responsible Tax Practices

We strive to conduct all aspects of our business in accordance with the highest standards of business ethics and to comply with all applicable tax laws and regulations that govern our industry globally.



Our Practices

Cybersecurity

Protecting the confidentiality, integrity and availability of our information systems is a top priority for Amneal. Our customers rely on us to reliably produce pharmaceuticals which are pure, safe and effective. Our employees, partners, suppliers and other third parties rely on us to be responsible custodians of their information. Maintaining their trust is critical to our success and fundamental to upholding our company values.

Cybersecurity Program

Our cybersecurity program includes policies and procedures designed to protect our systems and operations as well as sensitive information and data from anticipated cybersecurity threats. A key component to effective risk management includes multiple layers

of secure protocols to help prevent, detect and respond to cybersecurity threats. We use a variety of detective, preventive and corrective technologies, including, but not limited to:

- Email threat detection;
- Endpoint detection and response;
- Security operations center 24/7;
- Vulnerability scanning on both internal and externally-facing infrastructure;
- Next-generation firewalls with geographic access restriction for sensitive externally-facing systems;
- Multi-factor authentication for remote access and certain internal systems;
- Data loss prevention;
- Domain name service threat detection; and,

- Internal incident response procedures based on NIST Special Publication 800-61.

We also administer multiple cybersecurity-related training and awareness events annually. These include baseline cybersecurity training for all new employees, an annual, mandatory, interactive cybersecurity training for all who are assigned our user accounts, frequent cybersecurity topic awareness broadcast emails and targeted training to specific user groups. On a quarterly basis, our cybersecurity team also conducts scenario-based tabletop exercises with critical business teams to simulate disasters and cyberattacks, fine-tuning our business continuity plans and incident response procedures.

Cybersecurity Evaluation

Amneal’s cybersecurity processes are evaluated as part of an ongoing assessment of our internal control environment, which is informed by the six pillars of the NIST Cybersecurity Framework. We employ a third-party service provider to conduct periodic penetration tests and scan different parts of our IT environment for potential vulnerabilities. We prioritize critical and high vulnerabilities for swift remediation. Additionally, we employ a third-party service provider for continuous cybersecurity risk and vulnerability monitoring. We make continuous adjustments to system and network configurations to mitigate or remediate identified vulnerabilities.

Building cybersecurity resilience throughout our value chain is crucial. We perform risk management via an industry third-party risk management service provider for

all critical vendors, partners and systems meeting our risk management policy criteria, to minimize the likelihood and impact of malicious cybersecurity incidents. During the onboarding phase, our cybersecurity team performs a technological risk assessment and utilizes certain tools to detect external risks posed by the vendor, partner and/or system. Vendors identified as posing elevated risk are escalated to senior management for informed risk tolerance determination.

Data Privacy

Thriving businesses in today’s digital environment face evolving threats. As we grow to help more patients, our value from outside interests grows too. We take this responsibility seriously, constantly working to be one step ahead of potential attackers to prevent unauthorized users from ever gaining access to our sensitive and proprietary data.



Responsible Procurement


Respect for human rights is fundamental and we believe in the dignity of every human being. Guided by the United Nations Universal Declaration of Human Rights, the UN Global Compact, the International Bill of Human Rights, the International Labour Organization’s (ILO) Declaration on Fundamental Principles and Rights at Work, and the UN Guiding Principles on Business and Human Rights, we strive to conduct business ethically, fairly and with integrity.


We also expect the same type of commitment from our business partners. Our Code of Business Conduct, Global Supplier Code of Conduct and all applicable laws and regulations in the locations where our partners conduct

business lay out important values and standards we must follow. We expect that all employees, contingent workers and business partners familiarize themselves with and follow these codes.

In 2024, we also developed the Third-Party Due Diligence (TPDD) questionnaire to assist our team in screening suppliers for compatible values and legal compliance. Third-party due diligence enables us to identify the corruption risks that may be associated with a potential third-party.

Amneal will only engage with ethical, reputable and approved third-party representatives.





Appendix

IN THIS SECTION

- Global Reporting Initiative (GRI) Index
- Sustainability Accounting Standards Board (SASB) Index
- Forward-Looking Statements

Global Reporting Initiative (GRI) Index

Our reporting has been prepared with reference to the Global Reporting Initiative (GRI) Standards. Applicable GRI sector standards are not currently available. The information cited in this GRI content index is for the period from January 1, 2024 through December 31, 2024 unless otherwise stated. The table below links to the relevant information in our 2024 Responsible Business Report and on our corporate website.

Please note that grey shading on the chart is used to signify topics that are aligned with topic areas identified as material in the Company’s latest materiality assessment.

GRI 1: Foundation		
Statement of Use		Amneal has reported with reference to the GRI Standards for the period January 1, 2024 to December 31, 2024 unless otherwise noted in specific disclosures.
GRI 1 Used		GRI 1: Foundation 2021
GRI 2: General Disclosures		
2-1	Organizational details	See our most recent 10-K for a description of the business.
2-2	Entities included in the organization’s sustainability reporting	Amneal Pharmaceuticals, Inc. and its subsidiaries.
2-3	Reporting period, frequency and contact point	January 1, 2024 through December 31, 2024. Annual reporting ESG@amneal.com
2-4	Restatements of information	No restatements
2-5	External assurance	No
2-6	Activities, value chain and other business relationships	See our most recent 10-K for relevant details.
2-7	Employees	See Talent Recruitment, Retention & Development section of the 2024 Responsible Business Report.
2-9	Governance structure and composition	The Board does not have a formal policy on Board diversity as it relates to the selection of nominees for the Board. That said, the Board believes that diversity and a variety of experiences and viewpoints should be represented on the Board. In selecting a director nominee, the Nominating and Corporate Governance Committee focuses on skills, viewpoints, expertise or backgrounds that would complement the existing Board. The Committee regularly assesses the composition of the Board and seeks to identify candidates representing diverse experience at policy-making levels in business, management, marketing, finance, human resources, communications and other areas that are relevant to our activities. The Nominating and Corporate Governance Committee assesses its effectiveness in this regard when evaluating the composition of the Board. Amneal also places a high priority on creating a Board that reflects expanded experiences and perspectives, in support of our broader commitment to supporting a respectful workplace for all employees. Of the 11 members of the Board, two identify as female, eight identify as male and one prefers not to disclose. Additionally, three members of the Board identify as Asian, seven members of the Board identify as white, and one member of the Board did not disclose. Furthermore, one member of the Board identifies as LGBTQ+. See our Board of Directors website and our most recent Proxy Statement .
2-10	Nomination and selection of the highest governance body	See our most recent Proxy Statement .
2-11	Chair of the highest governance body	See our most recent Proxy Statement .

Global Reporting Initiative (GRI) Index

GRI 2: General Disclosures		
2-12	Role of the highest governance body in overseeing the management of impacts	Our Nominating and Corporate Governance Committee takes a leadership role in overseeing management’s handling of environmental, social and governance (ESG) matters of importance to the company.
2-13	Delegation of responsibility for managing impacts	Responsibility for managing impacts has been delegated to the ESG Task Force. See most recent 10-K as well as the Compliance & Business Ethics section of the 2024 Responsible Business Report herein for more information.
2-14	Role of the highest governance body in sustainability reporting	Responsibility for managing impacts has been delegated to the ESG Task Force. See most recent 10-K as well as the Compliance & Business Ethics section of the 2024 Responsible Business Report herein for more information.
2-15	Conflicts of interest	See Conflicts Committee Section of the Proxy Statement .
2-16	Communication of critical concerns	All material, legal and regulatory issues are reported in our annual and quarterly filings (10-K and 10-Qs).
2-17	Collective knowledge of the highest governance body	See our most recent Proxy Statement .
2-18	Evaluation of the performance of the highest governance body	See our most recent Proxy Statement .
2-19	Remuneration policies	See our most recent Proxy Statement .
2-20	Process to determine remuneration	See our most recent Proxy Statement .
2-21	Annual total compensation ratio	See our most recent Proxy Statement .
2-22	Statement on sustainable development strategy	As Amneal continues to expand and evolve, we are committed to doing so conscientiously. We aim to minimize our contribution to global greenhouse gas emissions and reduce our water footprint, ensuring our development is sustainable and responsible.
2-23	Policy commitments	See policies referenced throughout the 2024 Responsible Business Report as well as the policies listed on our policies website and Compliance and Ethics website .
2-24	Embedding policy commitments	See our policies website and Compliance and Ethics website .
2-26	Mechanisms for seeking advice and raising concerns	See Compliance & Business Ethics section of the 2024 Responsible Business Report.
2-27	Compliance with laws and regulations	Refer to all legal matters in the most recent 10-K and 10-Q filings. Additionally, see Compliance & Business Ethics section of the 2024 Responsible Business Report.
2-28	Membership associations	See memberships and associations referred to in the Access & Affordability section of the 2024 Responsible Business Report.
2-29	Approach to stakeholder engagement	We engage with stakeholders throughout the year and welcome feedback at any time. We also formally solicit feedback during key processes, such as materiality and risk assessments, to ensure the results appropriately consider perspectives of key stakeholders.
2-30	Collective bargaining agreements	No Collective Bargaining Agreements across the global workforce.

Global Reporting Initiative (GRI) Index

GRI 3: Material Topics		
3-1	Process to determine material topics	See Our Approach to Responsible Business section of the 2024 Responsible Business Report.
3-2	List of material topics	See Our Approach to Responsible Business section of the 2024 Responsible Business Report.
GRI 201: Economic Performance		
3-3	Management of the material topic	Refer to the most recent 10-K .
201-1	Direct economic value generated and distributed	Refer to the most recent 10-K .
201-2	Financial implications and other risks and opportunities due to climate change	See the most recent 10-K for considerations around the material risks and opportunities to the Company due to climate change.
201-4	Financial assistance received from government	Amneal receives government funds as a part of Medicaid, Medicare and other healthcare and drug pricing programs. See most recent 10-K for details.
GRI 203: Indirect Economic Impacts		
3-3	Management of the material topic	Refer to most recent 10-K for an understanding of Amneal’s indirect economic impacts through workforce, community engagement, healthcare affordability, and supplier and partner relationships.
203-2	Significant indirect economic impacts	Amneal has provided an estimated \$18.25 Billion in savings through our Affordable Medicines segment. See Access & Affordability section of the 2024 Responsible Business Report.
GRI 204: Procurement Practices		
3-3	Management of the material topic	Refer to the most recent 10-K for an understanding of Amneal’s procurement practices, as well as the Responsible Procurement section of the 2024 Responsible Business Report.
GRI 205: Anti-corruption		
3-3	Management of the material topic	See our Code of Business Conduct as well as the Compliance & Business Ethics section of the 2024 Responsible Business Report.
205-1	Operations assess for risks related to corruption	See discussion of Third-Party Due Diligence process within the Responsible Procurement section of the 2024 Responsible Business Report.
205-2	Communication and training about anti-corruption policies and procedures	Communication and training around anti-corruption policies is included within our Code of Business Conduct and is included in our Code of Business Conduct training. See Compliance & Business Ethics section of the 2024 Responsible Business Report. Additionally, Amneal has a Global Anti-Corruption Policy that all employees are expected to understand and follow.
205-3	Confirmed incidents of corruption and actions taken	No confirmed incidents of corruption in reporting year 2024.

Global Reporting Initiative (GRI) Index

GRI 206: Anti-competitive Behavior		
206-1	Legal actions for anti-competitive behavior, anti-trust, and monopoly practices	Refer to all legal matters in the most recent 10-K and 10-Q filings.
GRI 207: Tax		
3-3	Management of the material topic	See Responsible Tax Practices section of 2024 Responsible Business Report.
207-1	Approach to tax	See Responsible Tax Practices section of 2024 Responsible Business Report.
207-2	Tax governance, control, and risk management	Refer to the most recent 10-K for tax governance, control and risk management matters.
GRI 301: Materials		
3-3	Management of the material topic	See Renewable Energy & Energy Efficiency section of the 2024 Responsible Business Report.
GRI 302: Energy		
3-3	Management of the material topic	See Renewable Energy & Energy Efficiency section of the 2024 Responsible Business Report.
302-1	Energy consumption within the organization	See Renewable Energy & Energy Efficiency section of the 2024 Responsible Business Report.
302-4	Reduction of energy consumption	See Renewable Energy & Energy Efficiency section of the 2024 Responsible Business Report.
GRI 303: Water and Effluents		
3-3	Management of the material topic	See Waste & Water section of the 2024 Responsible Business Report.
303-5	Water consumption	See Waste & Water section of the 2024 Responsible Business Report.
GRI 305: Emissions		
3-3	Management of the material topic	See Renewable Energy & Energy Efficiency section of the 2024 Responsible Business Report.
305-1	Direct (Scope 1) GHG emissions	See Renewable Energy & Energy Efficiency section of the 2024 Responsible Business Report.
305-2	Energy indirect (Scope 2) GHG emissions	See Renewable Energy & Energy Efficiency section of the 2024 Responsible Business Report.
GRI 306: Waste		
3-3	Management of the material topic	See Waste & Water section of the 2024 Responsible Business Report.

Global Reporting Initiative (GRI) Index

GRI 308: Supplier Environmental Assessment		
3-3	Management of the material topic	See Responsible Procurement section of the Responsible Business Report 2024.
308-1	New suppliers that were screened using environmental criteria	See Responsible Procurement section of the Responsible Business Report 2024.
GRI 401: Employment		
3-3	Management of the material topic	See Talent Recruitment, Retention & Development section of the 2024 Responsible Business Report.
401-1	New employee hires and employee turnover	See Talent Recruitment, Retention & Development section of the 2024 Responsible Business Report.
401-3	Parental leave	See Talent Recruitment, Retention & Development section of the 2024 Responsible Business Report.
GRI 403: Occupational Health and Safety		
3-3	Management of the material topic	See Employee Health, Safety & Well-Being section of the 2024 Responsible Business Report.
403-1	Occupational health and safety management system	See Employee Health, Safety & Well-Being section of the 2024 Responsible Business Report.
403-2	Hazard identification, risk assessment, and incident investigation	See Employee Health, Safety & Well-Being section of the 2024 Responsible Business Report.
403-3	Occupational health services	See Employee Health, Safety & Well-Being section of the 2024 Responsible Business Report.
403-6	Promotion of worker health	See Employee Health, Safety & Well-Being section of the 2024 Responsible Business Report.
403-7	Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	See Employee Health, Safety & Well-Being section of the 2024 Responsible Business Report.
403-9	Work-related injuries	See Employee Health, Safety & Well-Being section of the 2024 Responsible Business Report.
403-10	Work-related ill health	See Employee Health, Safety & Well-Being section of the 2024 Responsible Business Report.
GRI 404: Training and Education		
3-3	Management of the material topic	See Talent Recruitment, Retention & Development section of the 2024 Responsible Business Report.
404-2	Programs for upgrading employee skills and transition assistance programs	See Talent Recruitment, Retention & Development section of the 2024 Responsible Business Report.
404-3	Percentage of employees receiving regular performance and career development reviews	Within our workforce, 97% of U.S.-based employees, 93% of India-based employees, and 98% of Ireland-based employees were eligible for and received an annual performance review for the performance year 2024.

Global Reporting Initiative (GRI) Index

GRI 405: Diversity and Equal Opportunity		
3-3	Management of the material topic	See Our Global Workforce section of the 2024 Responsible Business Report.
405-1	Diversity of governance bodies and employees	See Our Global Workforce section of the 2024 Responsible Business Report and latest Proxy Statement .
GRI 406: Non-discrimination		
3-3	Management of the material topic	Please refer to our Code of Conduct located on our Compliance and Ethics website .
GRI 408: Child Labor		
3-3	Management of the material topic	Please refer to our Code of Conduct, Global Supplier Code of Conduct and Human Rights Statement located on our Compliance and Ethics website .
GRI 409: Forced or Compulsory Labor		
3-3	Management of the material topic	Please refer to our Code of Conduct, Global Supplier Code of Conduct and Human Rights Statement located on our Compliance and Ethics website .
GRI 411: Rights of Indigenous Peoples		
3-3	Management of the material topic	Please refer to our Human Rights Statement located on our Compliance and Ethics website .
GRI 413: Local communities		
3-3	Management of the material topic	See Community Impact & Corporate Philanthropy section of the 2024 Responsible Business Report.
413-1	Operations with local community engagement, impact assessments, and development programs	See Community Impact & Corporate Philanthropy section of the 2024 Responsible Business Report.
GRI 414: Supplier Social Assessment		
3-3	Management of the material topic	See Responsible Procurement section of the 2024 Responsible Business Report.
414-1	New suppliers that were screened using social criteria	See Responsible Procurement section of the 2024 Responsible Business Report.
GRI 415: Public Policy		
3-3	Management of the material topic	See Access & Affordability section of the 2024 Responsible Business Report.
415-1	Political contributions	The organization did not make any political contributions in reporting year 2024.

Global Reporting Initiative (GRI) Index

GRI 416: Customer Health and Safety		
3-3	Management of the material topic	See Product Quality & Patient Safety section of the 2024 Responsible Business Report.
416-1	Assessment of the health and safety impacts of product and service categories	See Product Quality & Patient Safety section of the 2024 Responsible Business Report.
GRI 417: Marketing and Labeling		
3-3	Management of the material topic	Refer to the most recent 10-K for product marketing and labeling considerations.
417-1	Requirements for product and service information and labeling	Refer to the most recent 10-K for product marketing and labeling considerations.
417-2	Incidents of non-compliance concerning product and service information and labeling	Refer to the most recent 10-K for product marketing and labeling considerations.
417-3	Incidents of non-compliance concerning marketing communications	Refer to the most recent 10-K for product marketing and labeling considerations.
GRI 418: Customer Privacy		
3-3	Management of the material topic	See Cybersecurity section of the 2024 Responsible Business Report.

Sustainability Accounting Standards Board (SASB) Index

The following table provides data and information aligned with the Sustainability Standards Accounting Board (SASB) Health Care Sector — Biotechnology and Pharmaceuticals industry standard. The data and information presented below is for the period from January 1, 2024 through December 31, 2024 unless otherwise indicated in specific disclosures.

Table 1. Sustainability Disclosure Topics & Metrics

SASB TOPIC, CODE & METRIC	AMNEAL'S DISCLOSURE
SAFETY OF CLINICAL TRIAL PARTICIPANTS	
HC-BP-210a.1 Discussion, by region, of management process for ensuring quality and patient safety during clinical trials	See Product Quality & Patient Safety section of the 2024 Responsible Business Report.
HC-BP-210a.2 Number of inspections related to clinical trial management and pharmacovigilance that resulted in (1) entity voluntary remediation or (2) regulatory or administrative actions taken against the entity	No clinical trials in 2024.
HC-BP-210a.3 Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	All material, legal and regulatory issues are reported in our annual and quarterly filings (10-K and 10-Qs).
ACCESS TO MEDICINES	
HC-BP-240a.1 Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	See Access & Affordability and Scientific Innovation sections of the 2024 Responsible Business Report.
HC-BP-240a.2 List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	No Amneal products are on the list at time of reporting.
AFFORDABILITY & PRICING	
HC-BP-240b.1 Percentage change in: (1) weighted average list price and (2) weighted average net price across product portfolio compared to previous reporting period	
HC-BP-240b.2 Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous reporting period	
DRUG SAFETY	
HC-BP-250a.1 Products listed in public medical product safety or adverse event alert databases	FDA MedWatch Safety Alerts database.
HC-BP-250a.2 Number of fatalities associated with products	FDA Adverse Event Reporting System.

Sustainability Accounting Standards Board (SASB) Index

SASB TOPIC, CODE & METRIC	AMNEAL'S DISCLOSURE
DRUG SAFETY	
HC-BP-250a.3 (1) Number of recalls issues, (2) total units recalled	FDA Recall Database.
HC-BP-250a.4 Total amount of product accepted for take-back, reuse, or disposal	See product donations within the Community Impact & Corporate Philanthropy section of 2024 Responsible Business Report.
HC-BP-250a.5 Number of enforcement actions taken in response to violations of good manufacturing practices (GMP) or equivalent standards, by type	No FDA enforcement actions taken in 2024 in response to violations of current Good Manufacturing Practices (cGMP).
COUNTERFEIT DRUGS	
HC-BP-260a.1 Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in third-party audit programs for manufacturing and product quality	See Product Quality & Patient Safety section of the 2024 Responsible Business Report.
HC-BP-260a.2 Discussion of process for alerting customers and business partners to potential or known risks associated with counterfeit products	Drug Distributor Accreditation of website.
HC-BP-260a.3 Number of actions that led to raids, seizure, arrests, or filing of criminal charges related to counterfeit products	All material, legal, and regulatory issues are reported in our annual and quarterly filings (10-K and 10-Qs).
ETHICAL MARKETING	
HC-BP-270a.1 Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	All material, legal, and regulatory issues are reported in our annual and quarterly filings (10-K and 10-Qs).
HC-BP-270a.2 Description of code of ethics governing promotion of off-label use of products	In accordance with Amneal's Code of Conduct and supporting policies, Amneal follows applicable laws in the markets it serves, adhering at all times to product labeling requirements and promoting only uses that have been approved by regulatory authorities. Amneal prohibits off-label information, with limited exceptions as permitted and in accordance with applicable laws. Amneal further requires employees to report suspected violations of applicable laws, and any suspected violations of Amneal policies and procedures, directly to a supervisor, Corporate Compliance, Legal, or through the Amneal Ethics & Compliance hotline, Amtegrity.

Sustainability Accounting Standards Board (SASB) Index

SASB TOPIC, CODE & METRIC	AMNEAL'S DISCLOSURE
EMPLOYEE RECRUITMENT, DEVELOPMENT & RETENTION	
HC-BP-330a.1 Discussion of talent recruitment and retention efforts for scientists and research and development personnel	See Talent Recruitment, Retention & Development section of our 2024 Responsible Business Report.
HC-BP-330a.2 (1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	Annual Report Form 10-K: page 20
SUPPLY CHAIN MANAGEMENT	
HC-BP-430a.1 Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	See Responsible Procurement section of 2024 Responsible Business Report, as well as Amneal's statement on California Health and Safety Code and SB 657 in relation to supply chain management.
BUSINESS ETHICS	
HC-BP-510a.1 Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption	All material, legal and regulatory issues are reported in our annual and quarterly filings (10-K and 10-Qs).
HC-BP-510a.2 Description of code of ethics governing interactions with health care professionals	In accordance with Amneal's Code of Conduct and supporting policies, Amneal follows applicable laws in the markets it serves. Amneal further requires employees to report suspected violations of applicable laws, and any suspected violations of Amneal policies and procedures, directly to a supervisor, Corporate Compliance, Legal, or through the Amneal Ethics & Compliance hotline, Amtegrity.

Table 2. Activity Metrics

HC-BP-000.A Number of patients treated	Over 162 million scripts filled from our Affordable Medicines portfolio in the U.S. in 2024.
HC-BP-000.B Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	(1) Portfolio ; and (2) Research and development

Forward-Looking Statements

Certain statements contained in this Responsible Business Report regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including statements regarding our ESG goals, commitments and programs and other business plans, initiatives and objectives. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and similar words are intended to identify estimates and forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Amneal. The forward-looking statements contained herein are subject generally to the risks and uncertainties that are described from time to time in Amneal’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in Amneal’s most recent Annual Report on Form 10-K and in subsequent quarterly and period reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.





2024 FISCAL YEAR • PUBLISHED JUNE 2025

ADMINISTRATIVE OFFICE

U.S. Corporate Office

400 Crossing Boulevard, 3rd Floor
Bridgewater, New Jersey 08807
Phone: (908) 947-3120
Fax: (908) 947-3146

ESG INQUIRIES: ESG@amneal.com

MEDIA INQUIRIES: MediaRelations@amneal.com

INVESTOR INQUIRIES: invest@amneal.com

CORPORATE DEVELOPMENT INQUIRIES: BusinessDevelopment@amneal.com



AMNEAL 2024 Responsible Business Report